3025 POSTER Impact of pre-medication on the frequency of infusion-related reactions (IRRs) and efficacy in patients (pts) treated with cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): the MABEL study

H.Wilke; S.Siena; J.Thaler; A.Adenis; P.Preusser; J.Bridgewater; G.Gasparini; R.Esser; A.Loos; R.Glynne-Jones

首页> 外文期刊>European Journal of Cancer Supplements >3025 POSTER Impact of pre-medication on the frequency of infusion-related reactions (IRRs) and efficacy in patients (pts) treated with cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): the MABEL study

【24h】

3025 POSTER Impact of pre-medication on the frequency of infusion-related reactions (IRRs) and efficacy in patients (pts) treated with cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): the MABEL study

机译：3025 POSTER服药前对西妥昔单抗联合伊立替康治疗转移性结直肠癌（mCRC）的患者输注相关反应（IRR）的频率和疗效的影响：MABEL研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
H.Wilke; S.Siena; J.Thaler; A.Adenis; P.Preusser; J.Bridgewater; G.Gasparini; R.Esser; A.Loos; R.Glynne-Jones;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. 3055 POSTER Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study [J] . C.de Cerqueira Mathias, F.Perazzo, S.Simon, European Journal of Cancer Supplements . 2007,第4期

机译：3055 POSTER西妥昔单抗联合伊立替康在先前的伊立替康治疗期间或之后进展为转移性结直肠癌（mCRC）的患者（pts）：LABEL研究的最终结果
2. 3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study [J] . Y.Humblet, M.Peeters, H.Gelderblom, European Journal of Cancer Supplements . 2007,第4期

机译：在标准治疗下无或有轻微皮肤反应的转移性结直肠癌（mCRC）患者（pts）中的3017 POSTER西妥昔单抗剂量递增：EVEREST研究的药代动力学（PK），药效学（PD）和功效数据
3. 3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules [J] . F.Ciardiello, A.Cervantes, M.Vega-Villegas, European Journal of Cancer Supplements . 2007,第4期

机译：3040 POSTER转移性结直肠癌（mCRC）患者（pts）的西妥昔单抗（C）方案每2周（q2w）的最佳剂量：每周（q1w）的I期安全性，药代动力学（PK）和药效学（PD）研究和q2w时间表
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil irinotecan and oxaliplatin [O] . YOSHIKI HORIE, KENTARO YAMAZAKI, TARO FUNAKOSHI, -1

机译：氟尿嘧啶伊立替康和奥沙利铂治疗失败后转移性结直肠癌患者根据观察期根据皮疹严重程度可预测西妥昔单抗联合伊立替康的抗肿瘤功效
6. CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress [O] . M. Shah, A. Grothey, N. Tebbutt, 2018

机译：Canstem303C试验：在成年患者（PTS）中与先前治疗的转移性结肠直肠癌（MCRC）的成人患者（PTS）组合的纳帕布桑（NAPA）与5-氟尿嘧啶（5-FU），Leucovorin和Irinotecan（Folfiri）的相结合研究 - 试验

3025 POSTER Impact of pre-medication on the frequency of infusion-related reactions (IRRs) and efficacy in patients (pts) treated with cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): the MABEL study

著录项

相似文献

相关主题

期刊订阅